Your CRO Partner for
Preclinical Pharmacology
and In Vivo Services
Melior Discovery is a dedicated in vivo pharmacology CRO that strives to provide the highest quality service. We offer access to individual animal models and our theraTRACE® platform as contract research or on collaborative research basis. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.
Efficacy Models
Indications Discovery
In Vivo Services
Expert Consulting
Specialized Animal Models
Drug Repositioning
Your CRO Partner For
In Vivo Pharmacology
Melior Discovery is a dedicated in vivo pharmacology CRO that strives to provide the highest quality service. We offer access to individual animal models and our theraTRACE® platform as contract research or on collaborative research basis. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.
Melior Drug Discovery Philosophy
Watch the video
In Vivo Efficacy
Indications Discovery
Specialized Animal Models
Drug Repositioning
Andrew Reaume, PhD, CEO Melior Discovery
Trusted by the Top Leaders in Pharmacology
Melior Discovery's founding mission is drug repositioning - that is finding new uses for existing drugs.
State-of-the-art Preclinical Pharmacology Support
– Richard DiMarchi, PhD
Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences
Indiana University, Department of Chemistry
State-of-the-art Preclinical Pharmacology Support
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry
Phenotypic screening uncovers otherwise
unpredicted new uses for a drug
Learn about our in vivo services
contract research capabilities in most therapeutic areas.
Melior has pioneered a phenotypic
screening platform (theraTRACE® ) suited for in vivo services, drug repositioning, or for identifying novel indications from development-stage candidates.
Serving our community since 2005
Thousands of studies
Hundreds of compounds evaluated
Dozens of animal models of human disease
Our Drug Discovery Philosophy
Recent Studies using Phenotypic Screening
Development of a novel secondary phenotypic screen to identify hits within the mycobacterial protein synthesis pipeline.
Burke C, Jankute M, Moynihan P, Gonzalez Del Rio R, Li X, Esquivias J, Lelièvre J, Cox JAG, Sacchettini J, Besra GS
Background: Whole-cell phenotypic screening is the driving force behind modern anti-tubercular drug discovery efforts. F...
An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening.
Kinarivala N, Morsy A, Patel R, Carmona AV, Sajib MS, Raut S, Mikelis CM, Al-Ahmad A, Trippier PC
The neuronal ceroid lipofuscinoses (NCLs) are a family of rare lysosomal storage disorders. The most common form of NCL ...